• Proceedings of the Korean Institute of Information and Commucation Sciences Conference
• /
• 2015.10a
• /
• pp.958-960
• /
• 2015

Sickle cells possess a unique combination of traits that may enable their use as models for novel synthetic tumor targeting controlled release drug carriers with the ability to treat disseminated tumors in advanced metastatic disease. In this study, we assess the ability of light-activated release sickle cells to enhance tumor delivery of the fluorescent dye calcein by delayed photolysis controlled release compared to free systemic administration of calcein. Sickle cells from mouse models of the disease were shown to preferentially accumulate in tumors compared to adjacent tissue, in 4T1 tumors in mice on a time scale about 12 hours. Sickle cells photosensitized with protoporphyrin IX achieved delayed release of 50% of contents 8-16 hours after photoactivation, which was deemed useful for in vivo delivery of cargo to tumors given the tumor accumulation time of the sickle cells. Sickle cells may be useful as a model for new synthetic drug carrier particles with delayed photolysis controlled release properties.

• 대한위암학회:학술대회논문집
• /
• 2005.10a
• /
• pp.16-23
• /
• 2005

• Proceedings of the Korean Institute of Information and Commucation Sciences Conference
• /
• 2016.05a
• /
• pp.715-717
• /
• 2016

Conventional drug carriers such as liposomes, nanoparticles, polymer micelles, polymeric conjugate and lipid microemulsion for cancer chemotherapy shield normal tissues from toxic drugs to treat cancer cells in tumors. However, inaccurate tumor targeting uncontrolled drug release from the carriers and unwanted accumulation in healthy sites can limit treatment efficacy with current conventional drug carriers with insufficient concentrations of drugs in the tumors and unexpected side effects as a result. In this research, we examined the use of sickle red blood cells as a new drug carrier with novel tumor targeting and controlled release properties. Sickle red blood cells show natural tumor preferential accumulation without any manipulation and controlled drug release is possible using a hemolysis method with photosensitizers.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1992.05a
• /
• pp.19-19
• /
• 1992

해를 거듭할수록 증가추세에 있는 악성종양은 우리나라의 3대 사망원인 질환의 하나이다. 그러나 현재 암의 화학적 치료법은 40여종의 암치료제가 주종을 이루고 있으나 그 효과면에서 한계점에 도달하고 있어 식물추출물, 해양식물, 미생물 등으로부터 얻어지는 천연물 성분에서 강력하고 부작용이 적은 항암제를 발굴하기 위한 연구가 국내외에서 많이 수행되고 있다. 본 연구는 파푸아뉴기니아산 열대식물 13과 23종의 항암작용을 검색할 목적으로 실시하였는데, 실험동물은 ICR계의 암컷생쥐를 이용하였으며 Sarcoma 180 동물복수암세포에 대한 열대 식물 엑스 투여에 의한 수명 연장 효과를 측정함으로써 항암작용의 지표로 삼았다. 항암작용의 지표는 ILS(Increased Life Span)를 사용하였으며 ILS가 20％이상인 것을 항암성이 있는 것으로 간주하였다. 실험의 결과 Apocynaceae에 속하는 Plumiera rubra의 줄기껍질 및 잎 추출물 Leguminosae과의 Pterocarpus indicus의 잎 추출물과, 같은 과의 Derris trifoliata, Moraceae과의 Artocarpus altilis의 뿌리 및 줄기 껍질, 잎 추출물과 Sterculiaceae과의 Kleinhovia hospita의 잎 추출물, Verbenaceae과의 Vitex trifolia의 5과 5종 8시료가 의의있는 항암작용이 있는 것으로 나타났다.

• The Journal of Internal Korean Medicine
• /
• v.26 no.4
• /
• pp.753-760
• /
• 2005

목적 : 본 연구는 100명의 암환자를 대상으로 항암단의 항혈관형성 효과를 측정하기 위하여 고안되었다. 방법 : 100명의 암환자 전체의 치료전후의 VEGF, bFGF 및 혈소판 수치의 변화량을 측정하였고, 병기, 삶의 질 및 암종별로 환자를 나누어 각각의 치료전후의 VEGF, bFGF 및 혈소판 수치의 변화량을 측정하여 통계적 유의성을 살펴보았다. 결과 : 항암단으로 치료한 암환자의 bFGF 수치는 치료전 후 통계적으로 유의성 있게 감소하였다. 특히 유방암 환자에서 bFGF 수치의 감소가 눈에 띄었다. 비록 통계적으로 유의하지는 않았지만 VEGF수치도 항암단으로 치료 후 다소 감소하는 경향을 보였다. 결론 : 따라서 항암단이 암환자 치료에 있어 항혈관형성 약물로써 작용한다고 추론할 수 있다.

• Korean Journal of Clinical Pharmacy
• /
• v.21 no.3
• /
• pp.228-236
• /
• 2011

배경: 약물로 인한 Clostridium difficile-associated diarrhea (CDAD)는 널리 알려져 있으며 우리나라에서 항생제와 프로톤 펌프 억제제 소모량을 고려할 때 질환 치료과정에서의 CDAD 발생빈도 및 CDAD 유발 이전에 투여한 약물의 사용빈도와 CDAD의 치료방법을 조사할 필요성이 있다. 방법: 경상대학교 병원에서 2011년 1월부터 6월까지의 입원환자를 대상으로 대변 독소 검사에 의해 CDAD로 판명된 환자의 성별, 연령분포, 질환명, 입원병동, 재발률을 조사하였으며 CDAD 판명이전에 투여한 약제 및 CDAD 판명후 치료약제를 조사하였다. 결과: 연구기간 동안 CDAD 대변 독소 검사 의뢰된 환자수는 1,500명이었으며 CDAD 양성은 111명(9.3%)이었고, 재발은 29명(26.1%)이었다. CDAD를 주소로 입원한 환자는 17명 (15.3%)이었고, 나머지는 입원기간 중에 발생하였다. CDAD 양성인 환자의 연령대는 60대에서 32.4% (36/111명) 이었고, 내과병동에서 34.2%를 나타내었고, 재발률은 외과계 병동에서 41.4%로 가장 높게 나타났다. CDAD 환자의 17% (19/111명)은 항암제 투여 동안 발생하였으며 CDAD 발생 전 사용약물로는 세팔로스포린계 항생제가 162회로 가장 빈번하게 사용 되었으며, 히스타민2 수용체길항제 107회, 스테로이드 82회, 비 스테로이드 항염제 79회, 프로톤 펌프 억제제 77회, 하제 59회, 항암제가 33회 처방되었다. CDAD 치료약제로는 8종의 약제가 241회 처방 되었으며 metronidazole이 99회로 가장 빈번하게 사용되었고, vancomycin이 37회로 나타났다. 결론: 입원환자에 있어서 CDAD양성은 특히 고령의 암환자가 많아 항암제 투여 시에는 CDAD 발생에 주의해야 할것으로 보인다. CDAD의 치료약제로는 metronidazole이 vancomycin 보다 많이 사용되는 것으로 나타났다.

• Applied Chemistry for Engineering
• /
• v.29 no.2
• /
• pp.147-154
• /
• 2018

Currently, to overcome low therapeutic efficiencies and side effects of anticancer agents, the study of drug carrier based on polymers have been consistently investigated. Although the traditional drug carrier based on polymers displayed an excellent result and significant progress, there has been a problem with the side effect and low therapeutic efficiency because of the premature drug release before reached to the targeted region by the low stability in blood stream and sustained drug release. In this review article, to improve the problem of inefficient drug release, methods were suggested, which can maximize the therapeutic efficiency by increasing the stability in the blood stream and triggering drug release at the target site by introducing a stimuli-responsive substance to the non-toxic and biocompatible natural polymer chitosan.

• Journal of Digestive Cancer Research
• /
• v.5 no.1
• /
• pp.66-69
• /
• 2017

Approximately 40% of patients with colorectal cancer have metastatic lesions at the time of diagnosis, and chemotherapy is generally prescribed for these patients. Though several drugs are used, 5-FU has long been the backbone of chemotherapy for colorectal cancer. Capecitabine is an oral 5-FU prodrug approved by the FDA in 2005 and is used alone or in combination for treatment of colorectal cancer. Recently, capecitabine has been used for a number of off-label indications, including the treatment of advanced or metastatic colorectal cancer. Here, we report a rare case of a 59-year-old woman, diagnosed with metastatic colorectal cancer who first presented with abdominal discomfort and dyspepsia. She showed a partial response to palliative first line FOLFOX chemotherapy, which had to be stopped due to peripheral neuropathy, as a side effect. She was next put on a second line chemotherapy regimen with capecitabine alone, since then she showed good treatment response without any disease progression.

• Proceedings of the Korean Institute of Information and Commucation Sciences Conference
• /
• 2017.10a
• /
• pp.470-472
• /
• 2017

Currently, various studies using chemotherapy, such as surgical treatment, radiation or optical therapy, and chemotherapy, are underway. In addition, expensive chemotherapeutic drugs and large-scale equipment have been developed to improve the accuracy and therapeutic effect. However many side effects caused by misuse of the kind of light source, radiation, and cancer treatment have been observed. Therefore, in this paper, we propose a novel chemotherapeutic method by developing a customized cancer cell proliferation inhibition module based on a microcontroller that is relatively inexpensive, easy to operate, and able to operate in various wavelength light sources.

• Journal of Digestive Cancer Research
• /
• v.6 no.1
• /
• pp.16-24
• /
• 2018

Gastric cancer is not a single, uniform disease, but rather heterogeneous in nature. It is generally not possible to cure patients with inoperable advanced or metastatic stomach cancer. In the absence of chemotherapy, the median survival time is 3 to 6 months. Therefore, several studies have confirmed the superiority of chemotherapy to the best supportive treatment, in terms of improving the quality of life and prolonging life. Various chemotherapies have been used in the past to treat advanced gastric cancer. Recently, various target therapies and immunotherapy have been introduced. However, compared to other malignancies, the quality of life and life expectancy remain relatively poor in patients with gastric cancer. We expect to overcome these difficulties in the future, with better elucidation of the molecular biology of gastric cancer.